RAPT Therapeutics, Inc. (RAPT) Gains from Sales and Divestitures (2021 - 2024)
RAPT Therapeutics' Gains from Sales and Divestitures history spans 4 years, with the latest figure at $13500.0 for Q3 2024.
- For Q3 2024, Gains from Sales and Divestitures changed 0.0% year-over-year to $13500.0; the TTM value through Sep 2024 reached $13500.0, changed 0.0%, while the annual FY2023 figure was $13500.0, 0.0% changed from the prior year.
- Gains from Sales and Divestitures for Q3 2024 was $13500.0 at RAPT Therapeutics, roughly flat from $13500.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $14125.0 in Q1 2021 and bottomed at $13500.0 in Q1 2022.
- The 4-year median for Gains from Sales and Divestitures is $13500.0 (2022), against an average of $13666.7.
- The largest annual shift saw Gains from Sales and Divestitures decreased 4.42% in 2022 before it changed 0.0% in 2023.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $14125.0 in 2021, then dropped by 4.42% to $13500.0 in 2022, then changed by 0.0% to $13500.0 in 2023, then changed by 0.0% to $13500.0 in 2024.
- Per Business Quant, the three most recent readings for RAPT's Gains from Sales and Divestitures are $13500.0 (Q3 2024), $13500.0 (Q2 2024), and $13500.0 (Q1 2024).